Genedata forms Japanese cancer diagnostic pact:
This article was originally published in Clinica
Swiss firm Genedata has entered into a proteomics research collaboration with Japan's National Cancer Centre (NCC) that could lead to new diagnostic markers for cancer. NCC will use the Basel-based firm's Impressionist software to analyse the vast amounts of 2D-protein gel data generated from a range of different cancer types. As well as generating new targets for therapy and prevention, the partners hope to find marker proteins that will indicate the subclass of cancer.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.